Insights - Fennec Pharmaceuticals (FENC:NASDAQ) (FRX.TO:TSX) released the results of its long anticipated Phase 3 study. Interim data showed Fennec’s drug, sodium thiosulfate (“STS”) significantly reduces chemotherapy … Continue Reading
Long Ideas - The first efficacy data for SAGE-217, the oral follow-on to Sage Therapeutics’ (SAGE) injectable neurosteroid SAGE-547, are out, and they’re encouraging. Recall that SAGE-547 is … Continue Reading
Long Ideas - Last July, Ultragenyx Pharmaceutical (RARE) released positive results from a phase 3 study of its enzyme replacement therapy rhGUS (recombinant human beta-glucuronidase) in the lysosomal … Continue Reading
Long Ideas - After a negative vote from the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) and repeat signals that the regulatory agency was taking a hardline … Continue Reading
You're all done! We've sent you a confirmation email that includes a verification link. To access the page you're interested in, check your email inbox(including spam folder) and click the verification link.